Reading CDNA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CDNA free→Reading CDNA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CDNA free→QuarterlyIQ Insights · CDNA
The full factor breakdown (the numbers behind each rank). The overview page shows the same reads in short form; this is the depth.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted -8.91x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
Not enough signal yet.
Not investment advice. As of 2026-06-12.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.17 → $0.23 (+34.9% / 30d). 1 raised, 0 cut, 5 covering analysts.
0 upgrades, 0 downgrades / 30d. 43% of analysts rate Buy.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.